In addition, the trials reported, for the first time, a correlation between CSF BACE1 and its downstream marker Aβ42; however, the importance of routinely measuring BACE1 in daily clinical practice and AD clinical trials remains to be elucidated [63,64,65]. Here, BACE1 is linked to Alzheimer disease.